Multi-bed vascular disease and atherothrombosis: scope of the problem.
While atherosclerosis has traditionally been divided into three types of disease, coronary artery or coronary heart disease (CHD), cerebrovascular disease, and peripheral vascular or peripheral arterial disease (PAD), it is now clear that atherosclerosis is a systemic disease caused by the same pathologic processes regardless of the vascular bed involved. The burden of disease is enormous both in the US and around the world with 61,800,000 Americans affected with one or more types of CVD, responsible for 958,775 deaths annually at a cost of approximately US 329.2 billion dollars annually. Despite trends of decreasing cardiovascular mortality, the global burden of cardiovascular disease is expected to rise, with CHD and stroke becoming the first and fourth most common causes of mortality and morbidity globally. Atherosclerosis is a multibed process with a substantial portion of patients afflicted with disease in more than one bed, although often assymptomatic. Now that there are multiple therapies available to modify and treat atherosclerosis and atherosclerotic risk factors, identification and treatment of these patients are important since their leading cause of death is from co-existing cardiovascular disease.
The Zena and Michael Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA.
William Lane
WL
Duvall
David A
DA
Vorchheimer
D001161:Arteriosclerosis / Q000150:complications / Q000453:epidemiology*; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000453:epidemiology*; D012307:Risk Factors; D013927:Thrombosis / Q000150:complications / Q000453:epidemiology*